Within the last two months, fewer than five people became ill after receiving the unapproved product, according to Omaha.com. Details about the patients and the product used have not been released due to the investigation by Nebraska’s Department of Health and Human Services. The product that is the subject of the investigation is no longer available in the state.
The Nebraska state health department issued an advisory focusing on the risks related to unapproved stem cell, placental and umbilical cord blood-derived products, including exosomes, a type of extracellular vesicles that are released from cells. The advisory reminds healthcare providers that use of unapproved cell-based products could result in growth of tumors and infections.
The FDA in its statement reiterated that there are “currently no FDA-approved exosome products.”
“Certain clinics across the country… are now also offering exosome products to patients. They deceive patients with unsubstantiated claims about the potential for these products to prevent, treat or cure various diseases or conditions,” the statement reads.
The FDA urged patients considering treatment with exosome products to ask whether they have been reviewed by the FDA and potential risks.
More articles on clinical leadership & infection control:
CMS cites Houston hospital over C-section death
6 hospitals seeking CMOs
Vermont hospital extends OR closure into 2020 as sickening smell remains unsolved
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
